<DOC>
	<DOCNO>NCT00667342</DOCNO>
	<brief_summary>This study adopt novel strategy first-line treatment osteosarcoma combine chemotherapy anti-angiogenic therapy use bevacizumab ( AvastinÂ® ) , humanize monoclonal antibody vascular endothelial growth factor ( VEGF ) . Chemotherapy localize disease comprise 3-drug regimen ( cisplatin , doxorubicin , high-dose methotrexate ) . Chemotherapy metastatic unresectable disease comprise cisplatin-based regimen include high-dose methotrexate , doxorubicin , ifosfamide , etoposide .</brief_summary>
	<brief_title>A Study Bevacizumab Combination With Chemotherapy Treatment Osteosarcoma</brief_title>
	<detailed_description>This comprehensive study use novel agent target angiogenesis ( bevacizumab ) combination conventional chemotherapy treatment osteosarcoma . Bevacizumab , monoclonal antibody vascular endothelial growth factor ( VEGF ) , show stop growth new blood vessel tumor , laboratory patient type cancer . Bevacizumab improved effect chemotherapy adult patient different type cancer increase tumor response increase chance survival . This study two main goal : - To find bevacizumab combine safely chemotherapy osteosarcoma - To find add bevacizumab chemotherapy beneficial treating osteosarcoma . The chemotherapy drug use study commonly use treat osteosarcoma . Patients non-metastatic resectable tumor receive bevacizumab chemotherapy comprise cisplatin , doxorubicin high-dose methotrexate . Patients metastatic tumor tumor remove surgery receive bevacizumab chemotherapy comprise cisplatin , doxorubicin high-dose methotrexate , ifosfamide etoposide . If tumor remove surgery , surgery perform 10 week chemotherapy follow additional chemotherapy . After completion active therapy , patient 's response therapy follow approximately 5 year .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Histiocytoma</mesh_term>
	<mesh_term>Histiocytoma , Benign Fibrous</mesh_term>
	<mesh_term>Histiocytoma , Malignant Fibrous</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patient must newly diagnose highgrade , biopsy proven , osteosarcoma malignant fibrous histiocytoma ( MFH ) bone history prior chemotherapy radiation ; Participant able perform task daily activity define study guideline Patient meet establish guideline adequate function kidney , liver , heart bone marrow Participants meet requirement define eligibility portion study recent major surgical procedure injury Known bleeding diathesis , platelet disorder coagulopathy Thrombosis Cardiac disease hypertension Significant proteinuria Central nervous system disease Gastrointestinal perforation/abdominal fistula Osteosarcoma MFH bone second malignancy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>